Peptide Comparison

Compare peptides side-by-side.

Pick up to four peptides and compare mechanism, evidence grade, pharmacokinetics, administration and risk profile in a single view.

Selection · 3 / 4

Save & share

Save a set to reload it later on this device, or copy a share link to send the exact comparison to someone else.

Export comparison

Download the full side-by-side table as a landscape PDF for reading, or a CSV for spreadsheets and further analysis.

AI comparison summary

Biggest differences across Pinealon · Dihexa · Tesamorelin

Focused on evidence grade, pharmacokinetics, and risks/interactions — with inline citations to the primary references on each peptide page.

Click Generate summary to have AI highlight the biggest differences between the peptides you've selected.

Pinealon

Grade CCognitive

Overview

Evidence grade: Grade C
Category: Cognitive
Primary focus: Cognitive resilience (research)
Summary: Russian preclinical studies report neuroprotective and anti-aging effects on cognition. Independent replication and Western clinical trials are absent.

Mechanism

Mechanism of action: Tripeptide (Glu-Asp-Arg) developed within the Russian bioregulator framework. Hypothesized to cross the blood–brain barrier and modulate neuronal gene expression, antioxidant defenses, and apoptosis.
Evidence explainer: Grade C — mechanistic hypothesis and animal or in-vitro data only. No controlled human trials. Treat as experimental; risks are not fully known.

Pharmacokinetics

Route: Intranasal or subcutaneous
Half-life: Short, hours
PK notes: Pinealon is administered intranasal or subcutaneous with an approximate systemic half-life of Short, hours. Steady-state and tissue-level effects can outlast plasma concentration, which is why dosing frequency (Daily) is designed to match receptor kinetics rather than plasma exposure. Tripeptide (Glu-Asp-Arg) developed within the Russian bioregulator framework. Hypothesized to cross the blood–brain barrier and modulate neuronal gene expression, antioxidant defenses, and apoptosis.

Administration

Typical dose: 1–10 mg
Frequency: Daily
Cycle length: 10–20 day cycles, 1–2× per year
Timing: Morning
Protocol steps: Route: Intranasal or subcutaneous. Typical starting dose 1–10 mg, Daily.
Timing: Morning — keep it the same each dosing day to make effects legible.
Cycle length: 10–20 day cycles, 1–2× per year. Reassess with bloods and symptom logs before repeating.
Rotate sites across the abdomen (avoiding a 2 cm radius around the navel), outer thighs and flanks. Never inject through a bruise or mole.

Benefits

Reported benefits: Reported neuroprotection in rodent ischemia models
Reduced oxidative stress markers
Subjective cognitive and sleep improvements (anecdotal)
Common stacks: Epithalon, Magnesium glycinate

Risks

Side effects: Largely unknown long-term
Injection site or nasal irritation
Contraindications: Active malignancy
Pregnancy
Interactions: Other bioregulator peptides — Often stacked; interactions not characterized.
Legal status: Research chemical; not approved for human therapeutic use.

Dihexa

Grade CCognitive

Overview

Evidence grade: Grade C
Category: Cognitive
Primary focus: Cognitive plasticity (preclinical)
Summary: Animal studies show dramatic effects on spatial memory and synaptic density. No controlled human data exists; safety profile in humans is unknown.

Mechanism

Mechanism of action: Hexapeptide derivative of angiotensin IV. Reported to potentiate hepatocyte growth factor (HGF)/c-Met signaling, promoting synaptogenesis and dendritic spine formation in preclinical models.
Evidence explainer: Grade C — mechanistic hypothesis and animal or in-vitro data only. No controlled human trials. Treat as experimental; risks are not fully known.

Pharmacokinetics

Route: Oral or transdermal (research)
Half-life: Estimated short (oral bioavailability reported)
PK notes: Dihexa is administered oral or transdermal (research) with an approximate systemic half-life of Estimated short (oral bioavailability reported). Steady-state and tissue-level effects can outlast plasma concentration, which is why dosing frequency (Daily) is designed to match receptor kinetics rather than plasma exposure. Hexapeptide derivative of angiotensin IV. Reported to potentiate hepatocyte growth factor (HGF)/c-Met signaling, promoting synaptogenesis and dendritic spine formation in preclinical models.

Administration

Typical dose: 8–45 mg (anecdotal)
Frequency: Daily
Cycle length: Short cycles only
Timing: Morning
Protocol steps: Route: Oral or transdermal (research). Typical starting dose 8–45 mg (anecdotal), Daily.
Timing: Morning — keep it the same each dosing day to make effects legible.
Cycle length: Short cycles only. Reassess with bloods and symptom logs before repeating.

Benefits

Reported benefits: Synaptogenesis in rodent hippocampus
Reversal of scopolamine-induced cognitive deficits (rodents)
Reported subjective cognitive enhancement (anecdotal)
Common stacks: Omega-3 EPA/DHA, Lion's Mane

Risks

Side effects: Unknown long-term human safety
Theoretical proliferative risk via HGF/c-Met
Contraindications: Active or prior malignancy
Pregnancy
Family cancer history
Interactions: Tyrosine kinase modulators — Mechanistic overlap with c-Met signaling.
Legal status: Research chemical. Not approved for human use. Significant unknown oncologic risk.

Tesamorelin

Grade AGrowth Hormone

Overview

Evidence grade: Grade A
Category: Growth Hormone
Primary focus: Visceral fat, growth hormone axis
Summary: The most rigorously evidenced peptide on this site, and the only one here approved by a major regulator. FDA-approved in 2010 as Egrifta for excess abdominal fat in HIV-associated lipodystrophy, on the back of phase 3 trials showing a 15-18% reduction in visceral adipose tissue against placebo. Everything outside that indication — the anti-ageing and body-composition uses it is sold for — is extrapolation from a population that is not you.

Mechanism

Mechanism of action: A synthetic analogue of the full 44-amino-acid human growth hormone releasing factor, with a hexenoyl group on the N-terminus that slows enzymatic degradation. It binds pituitary GHRH receptors to restore pulsatile growth hormone secretion, raising IGF-1 and shifting adipose metabolism preferentially against visceral rather than subcutaneous fat.
Evidence explainer: Grade A — supported by multiple randomised human trials or an approved regulatory indication. Mechanism, dosing and safety are well characterised in humans.

Pharmacokinetics

Route: Subcutaneous injection
Half-life: ~26 minutes in plasma; the growth hormone rise it triggers persists 4-6 hours
PK notes: Tesamorelin is administered subcutaneous injection with an approximate systemic half-life of ~26 minutes in plasma; the growth hormone rise it triggers persists 4-6 hours. Steady-state and tissue-level effects can outlast plasma concentration, which is why dosing frequency (Once daily) is designed to match receptor kinetics rather than plasma exposure. A synthetic analogue of the full 44-amino-acid human growth hormone releasing factor, with a hexenoyl group on the N-terminus that slows enzymatic degradation. It binds pituitary GHRH receptors to restore pulsatile growth hormone secretion, raising IGF-1 and shifting adipose metabolism preferentially against visceral rather than subcutaneous fat.

Administration

Typical dose: 2 mg (1.28 mg for the newer F8/WR formulation)
Frequency: Once daily
Cycle length: 26 weeks in the pivotal trials; benefit reverses on stopping
Timing: Bedtime, to sit with the natural overnight GH pulse
Protocol steps: Route: Subcutaneous injection. Typical starting dose 2 mg (1.28 mg for the newer F8/WR formulation), Once daily.
Timing: Bedtime, to sit with the natural overnight GH pulse — keep it the same each dosing day to make effects legible.
Cycle length: 26 weeks in the pivotal trials; benefit reverses on stopping. Reassess with bloods and symptom logs before repeating.
Rotate sites across the abdomen (avoiding a 2 cm radius around the navel), outer thighs and flanks. Never inject through a bruise or mole.

Benefits

Reported benefits: 15-18% reduction in visceral adipose tissue versus placebo in phase 3 trials
Improved triglycerides and cholesterol alongside the fat loss
Raises IGF-1 without the supraphysiological spikes of exogenous growth hormone
Does not reduce subcutaneous fat, which is metabolically less harmful
Common stacks: Zone 2 cardio, Resistance training, Regular HbA1c and IGF-1 monitoring

Risks

Side effects: Injection site reactions, the commonest complaint in trials
Joint pain and peripheral oedema, both dose-related and GH-mediated
Raised blood glucose and reduced insulin sensitivity — monitor if prediabetic
Carpal tunnel symptoms at higher exposures
Contraindications: Active malignancy — growth hormone is mitogenic and IGF-1 is a growth signal
Pituitary disease, pituitary surgery or head irradiation
Pregnancy and lactation
Diabetic retinopathy
Interactions: Insulin and sulfonylureas — Tesamorelin worsens insulin sensitivity; glycaemic control may need adjusting.
Corticosteroids — Blunt the GH response and add their own metabolic burden.
GHRH analogues (CJC-1295) — Same receptor. Stacking adds risk, not effect.
Legal status: FDA-approved as Egrifta and Egrifta SV/WR for HIV-associated lipodystrophy only, and prescription-only. Use for body composition or anti-ageing is off-label. Material sold online as research-grade tesamorelin is not the approved product and carries no purity guarantee.

Attribute	Pinealon Grade CCognitive	Dihexa Grade CCognitive	Tesamorelin Grade AGrowth Hormone
Overview
Evidence grade	Grade C	Grade C	Grade A
Category	Cognitive	Cognitive	Growth Hormone
Primary focus	Cognitive resilience (research)	Cognitive plasticity (preclinical)	Visceral fat, growth hormone axis
Summary	Russian preclinical studies report neuroprotective and anti-aging effects on cognition. Independent replication and Western clinical trials are absent.	Animal studies show dramatic effects on spatial memory and synaptic density. No controlled human data exists; safety profile in humans is unknown.	The most rigorously evidenced peptide on this site, and the only one here approved by a major regulator. FDA-approved in 2010 as Egrifta for excess abdominal fat in HIV-associated lipodystrophy, on the back of phase 3 trials showing a 15-18% reduction in visceral adipose tissue against placebo. Everything outside that indication — the anti-ageing and body-composition uses it is sold for — is extrapolation from a population that is not you.
Mechanism
Mechanism of action	Tripeptide (Glu-Asp-Arg) developed within the Russian bioregulator framework. Hypothesized to cross the blood–brain barrier and modulate neuronal gene expression, antioxidant defenses, and apoptosis.	Hexapeptide derivative of angiotensin IV. Reported to potentiate hepatocyte growth factor (HGF)/c-Met signaling, promoting synaptogenesis and dendritic spine formation in preclinical models.	A synthetic analogue of the full 44-amino-acid human growth hormone releasing factor, with a hexenoyl group on the N-terminus that slows enzymatic degradation. It binds pituitary GHRH receptors to restore pulsatile growth hormone secretion, raising IGF-1 and shifting adipose metabolism preferentially against visceral rather than subcutaneous fat.
Evidence explainer	Grade C — mechanistic hypothesis and animal or in-vitro data only. No controlled human trials. Treat as experimental; risks are not fully known.	Grade C — mechanistic hypothesis and animal or in-vitro data only. No controlled human trials. Treat as experimental; risks are not fully known.	Grade A — supported by multiple randomised human trials or an approved regulatory indication. Mechanism, dosing and safety are well characterised in humans.
Pharmacokinetics
Route	Intranasal or subcutaneous	Oral or transdermal (research)	Subcutaneous injection
Half-life	Short, hours	Estimated short (oral bioavailability reported)	~26 minutes in plasma; the growth hormone rise it triggers persists 4-6 hours
PK notes	Pinealon is administered intranasal or subcutaneous with an approximate systemic half-life of Short, hours. Steady-state and tissue-level effects can outlast plasma concentration, which is why dosing frequency (Daily) is designed to match receptor kinetics rather than plasma exposure. Tripeptide (Glu-Asp-Arg) developed within the Russian bioregulator framework. Hypothesized to cross the blood–brain barrier and modulate neuronal gene expression, antioxidant defenses, and apoptosis.	Dihexa is administered oral or transdermal (research) with an approximate systemic half-life of Estimated short (oral bioavailability reported). Steady-state and tissue-level effects can outlast plasma concentration, which is why dosing frequency (Daily) is designed to match receptor kinetics rather than plasma exposure. Hexapeptide derivative of angiotensin IV. Reported to potentiate hepatocyte growth factor (HGF)/c-Met signaling, promoting synaptogenesis and dendritic spine formation in preclinical models.	Tesamorelin is administered subcutaneous injection with an approximate systemic half-life of ~26 minutes in plasma; the growth hormone rise it triggers persists 4-6 hours. Steady-state and tissue-level effects can outlast plasma concentration, which is why dosing frequency (Once daily) is designed to match receptor kinetics rather than plasma exposure. A synthetic analogue of the full 44-amino-acid human growth hormone releasing factor, with a hexenoyl group on the N-terminus that slows enzymatic degradation. It binds pituitary GHRH receptors to restore pulsatile growth hormone secretion, raising IGF-1 and shifting adipose metabolism preferentially against visceral rather than subcutaneous fat.
Administration
Typical dose	1–10 mg	8–45 mg (anecdotal)	2 mg (1.28 mg for the newer F8/WR formulation)
Frequency	Daily	Daily	Once daily
Cycle length	10–20 day cycles, 1–2× per year	Short cycles only	26 weeks in the pivotal trials; benefit reverses on stopping
Timing	Morning	Morning	Bedtime, to sit with the natural overnight GH pulse
Protocol steps	Route: Intranasal or subcutaneous. Typical starting dose 1–10 mg, Daily. Timing: Morning — keep it the same each dosing day to make effects legible. Cycle length: 10–20 day cycles, 1–2× per year. Reassess with bloods and symptom logs before repeating. Rotate sites across the abdomen (avoiding a 2 cm radius around the navel), outer thighs and flanks. Never inject through a bruise or mole.	Route: Oral or transdermal (research). Typical starting dose 8–45 mg (anecdotal), Daily. Timing: Morning — keep it the same each dosing day to make effects legible. Cycle length: Short cycles only. Reassess with bloods and symptom logs before repeating.	Route: Subcutaneous injection. Typical starting dose 2 mg (1.28 mg for the newer F8/WR formulation), Once daily. Timing: Bedtime, to sit with the natural overnight GH pulse — keep it the same each dosing day to make effects legible. Cycle length: 26 weeks in the pivotal trials; benefit reverses on stopping. Reassess with bloods and symptom logs before repeating. Rotate sites across the abdomen (avoiding a 2 cm radius around the navel), outer thighs and flanks. Never inject through a bruise or mole.
Benefits
Reported benefits	Reported neuroprotection in rodent ischemia models Reduced oxidative stress markers Subjective cognitive and sleep improvements (anecdotal)	Synaptogenesis in rodent hippocampus Reversal of scopolamine-induced cognitive deficits (rodents) Reported subjective cognitive enhancement (anecdotal)	15-18% reduction in visceral adipose tissue versus placebo in phase 3 trials Improved triglycerides and cholesterol alongside the fat loss Raises IGF-1 without the supraphysiological spikes of exogenous growth hormone Does not reduce subcutaneous fat, which is metabolically less harmful
Common stacks	Epithalon, Magnesium glycinate	Omega-3 EPA/DHA, Lion's Mane	Zone 2 cardio, Resistance training, Regular HbA1c and IGF-1 monitoring
Risks
Side effects	Largely unknown long-term Injection site or nasal irritation	Unknown long-term human safety Theoretical proliferative risk via HGF/c-Met	Injection site reactions, the commonest complaint in trials Joint pain and peripheral oedema, both dose-related and GH-mediated Raised blood glucose and reduced insulin sensitivity — monitor if prediabetic Carpal tunnel symptoms at higher exposures
Contraindications	Active malignancy Pregnancy	Active or prior malignancy Pregnancy Family cancer history	Active malignancy — growth hormone is mitogenic and IGF-1 is a growth signal Pituitary disease, pituitary surgery or head irradiation Pregnancy and lactation Diabetic retinopathy
Interactions	Other bioregulator peptides — Often stacked; interactions not characterized.	Tyrosine kinase modulators — Mechanistic overlap with c-Met signaling.	Insulin and sulfonylureas — Tesamorelin worsens insulin sensitivity; glycaemic control may need adjusting. Corticosteroids — Blunt the GH response and add their own metabolic burden. GHRH analogues (CJC-1295) — Same receptor. Stacking adds risk, not effect.
Legal status	Research chemical; not approved for human therapeutic use.	Research chemical. Not approved for human use. Significant unknown oncologic risk.	FDA-approved as Egrifta and Egrifta SV/WR for HIV-associated lipodystrophy only, and prescription-only. Use for body composition or anti-ageing is off-label. Material sold online as research-grade tesamorelin is not the approved product and carries no purity guarantee.

← Back to all peptides